DTU
DTU

Professor Rury Holman

Picture of Rury Holman Highly Cited Researcher

Position:Emeritus Director

PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240

Email:rury.holman@dtu.ox.ac.uk

ORCID ID0000-0002-1256-874X

Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.

Latest publications

Manuscript
Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study
Laura M. Güdemann et al.
The Lancet Regional Health – Europe 2026;61:101547

Manuscript
The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review
Ashni Goshrani et al.
Diabetes Care 2025

Manuscript
Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy
Eberhard Standl et al.
Cardiovasc Diabetol. 2025;14:441

Manuscript
Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS Outcomes Model using TECOS and EXSCEL data
Coleman RL et al.
Diabetes Obes Metab. 2025

Manuscript
International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL
Philip M Clarke et al.
Diabetes Care 2025;48:1925-1931

Manuscript
Utilization of proteomic surrogates for early detection of unexpected drug benefits
Jessica Chadwick et al.
J Clin Pharmacol. 2025;65:1460-1473